Nutralife Biosciences Inc
NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil derived from industrial hemp; tinctures; topical lotions and oils applied directly to the skin to treat pain or inflammation; face creams; massage oils; nutrace… Read more
Nutralife Biosciences Inc (NLBS) - Net Assets
Latest net assets as of September 2022: $-2.32 Million USD
Based on the latest financial reports, Nutralife Biosciences Inc (NLBS) has net assets worth $-2.32 Million USD as of September 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.03 Million) and total liabilities ($8.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.32 Million |
| % of Total Assets | -38.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | -207.87% |
| 10-Year Change | N/A |
| Growth Volatility | 163.59 |
Nutralife Biosciences Inc - Net Assets Trend (2012–2021)
This chart illustrates how Nutralife Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nutralife Biosciences Inc (2012–2021)
The table below shows the annual net assets of Nutralife Biosciences Inc from 2012 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | $-712.53K | -336.63% |
| 2020-12-31 | $301.11K | -81.05% |
| 2019-12-31 | $1.59 Million | +94.92% |
| 2018-12-31 | $815.25K | +23.43% |
| 2017-12-31 | $660.52K | +353.28% |
| 2016-12-31 | $-260.79K | -44.34% |
| 2015-12-31 | $-180.68K | +80.97% |
| 2014-12-31 | $-949.33K | -1235.20% |
| 2013-12-31 | $-71.10K | +57.45% |
| 2012-12-31 | $-167.10K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nutralife Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4686089400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.13K | % |
| Other Components | $46.83 Million | % |
| Total Equity | $-712.53K | 100.00% |
Nutralife Biosciences Inc Competitors by Market Cap
The table below lists competitors of Nutralife Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
THROMBOGENICS
BE:TG4
|
$9.73K |
|
122830
KO:122830
|
$9.77K |
|
PTS Inc
PINK:PTSH
|
$9.79K |
|
Lake House Printers and Publishers PLC
CM:LPRTN0000
|
$9.79K |
|
QRT
WAR:QRT
|
$9.72K |
|
Central Finance Company PLC
CM:CFINN0000
|
$9.71K |
|
Jr Global Reit
KO:348950
|
$9.70K |
|
KST BETEILIG N (KSW.SG)
STU:KSW
|
$9.70K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nutralife Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 301,110 to -712,530, a change of -1,013,640 (-336.6%).
- Net loss of 7,683,241 reduced equity.
- New share issuances of 348,000 increased equity.
- Other factors increased equity by 6,321,601.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.68 Million | -1078.3% |
| Share Issuances | $348.00K | +48.84% |
| Other Changes | $6.32 Million | +887.2% |
| Total Change | $- | -336.63% |
Book Value vs Market Value Analysis
This analysis compares Nutralife Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.01 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $-0.04 | $0.00 | x |
| 2015-12-31 | $-0.01 | $0.00 | x |
| 2016-12-31 | $-0.01 | $0.00 | x |
| 2017-12-31 | $0.01 | $0.00 | x |
| 2018-12-31 | $0.01 | $0.00 | x |
| 2019-12-31 | $0.01 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nutralife Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1226.14%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-504.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -306.34% | 0.51x | 0.00x | $-371.04K |
| 2013 | 0.00% | -348.52% | 0.92x | 0.00x | $-2.08 Million |
| 2014 | 0.00% | -3333.20% | 0.18x | 0.00x | $-1.98 Million |
| 2015 | 0.00% | -1083.03% | 0.09x | 0.00x | $-2.08 Million |
| 2016 | 0.00% | -390.09% | 0.16x | 0.00x | $-1.50 Million |
| 2017 | -3577.33% | -1319.94% | 1.88x | 1.44x | $-23.70 Million |
| 2018 | -254.47% | -55.90% | 2.03x | 2.25x | $-2.16 Million |
| 2019 | -252.18% | -187.82% | 0.48x | 2.81x | $-4.17 Million |
| 2020 | -963.99% | -231.15% | 0.27x | 15.63x | $-2.93 Million |
| 2021 | 0.00% | -1226.14% | 0.13x | 0.00x | $-7.61 Million |
Industry Comparison
This section compares Nutralife Biosciences Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nutralife Biosciences Inc (NLBS) | $-2.32 Million | 0.00% | N/A | $9.73K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |